Investor Alert: How to See Through Corporate Earnings Smoke and Mirrors

In August 2015, pharmaceutical company Valeant was riding high. Now, after greater scrutiny and criticism, Valeant's stock is down more than 85 percent from its high. A major cause of the rise — and the fall — was so-called pro forma results.